Achilles Therapeutics plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACHL research report →
Companywww.achillestx.com
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer.
- CEO
- Iraj Ali
- IPO
- 2021
- Employees
- 204
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $60.83M
- P/E
- -0.85
- P/S
- 0.00
- P/B
- 0.42
- EV/EBITDA
- 0.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.05%
- ROIC
- -50.85%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-69,665,000 · 2.12%
- EPS
- $-1.74 · 4.40%
- Op Income
- $-75,255,000
- FCF YoY
- 26.10%
Performance & Tape
- 52W High
- $1.51
- 52W Low
- $0.63
- 50D MA
- $1.33
- 200D MA
- $1.03
- Beta
- 1.25
- Avg Volume
- 1.28M
Get TickerSpark's AI analysis on ACHL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ACHL Coverage
We haven't published any research on ACHL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACHL Report →